BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-71. [PMID: 17074012 DOI: 10.1111/j.1440-1746.2006.04768.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, An Y, Wang L. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis: Hepatitis B virus natural mutation rate. J Gastroenterol Hepatol 2015;30:252-61. [DOI: 10.1111/jgh.12831] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
2 Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009;53:2762-72. [PMID: 19433559 DOI: 10.1128/AAC.00130-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Tan YW, Ye Y, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B. World J Gastroenterol 2015; 21(7): 2089-2095 [PMID: 25717242 DOI: 10.3748/wjg.v21.i7.2089] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus. Front Pharmacol 2021;12:648170. [PMID: 33935748 DOI: 10.3389/fphar.2021.648170] [Reference Citation Analysis]
6 Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 2012;7:e32789. [PMID: 22479339 DOI: 10.1371/journal.pone.0032789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
7 Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP, Jin L, Hou J. Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Sci Rep 2015;5:17123. [PMID: 26599443 DOI: 10.1038/srep17123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
8 Meneghello BHDS, Soares MMCN, Silva VCM, Lemos MF, Cervato MC, Caetano Filho J, Sitnik R, Estécio TCH, Compri AP, Pinho JRR, Moreira RC. Hepatitis B in the Northwestern region of Sao Paulo State: genotypes and resistance mutations. Rev Inst Med Trop Sao Paulo 2021;63:e78. [PMID: 34755817 DOI: 10.1590/S1678-9946202163078] [Reference Citation Analysis]